| Literature DB >> 34976202 |
Xirui Chen1, Lu Ding2, Xiaolin Huang1, Yonghua Xiong1,3.
Abstract
Lateral flow immunoassay (LFIA) with gold nanoparticles (AuNPs) as signal reporters is a popular point-of-care diagnostic technique. However, given the weak absorbance of traditional 20-40 nm spherical AuNPs, their sensitivity is low, which greatly limits the wide application of AuNP-based LFIA. With the rapid advances in materials science and nanotechnology, the synthesis of noble metal nanoparticles (NMNPs) has enhanced physicochemical properties such as optical, plasmonic, catalytic, and multifunctional activity by simply engineering their physical parameters, including the size, shape, composition, and external structure. Using these engineered NMNPs as an alternative to traditional AuNPs, the sensitivity of LFIA has been significantly improved, thereby greatly expanding the working range and application scenarios of LFIA, particularly in trace analysis. Therefore, in this review, we will focus on the design of engineered NMNPs and their demonstration in improving LFIA. We highlight the strategies available for tailoring NMNP designs, the effect of NMNP engineering on their performance, and the working principle of each engineering design for enhancing LFIA. Finally, current challenges and future improvements in this field are briefly discussed. © The author(s).Entities:
Keywords: engineering; lateral flow immunoassay; nanoparticle design; noble metal nanoparticles
Mesh:
Substances:
Year: 2022 PMID: 34976202 PMCID: PMC8692915 DOI: 10.7150/thno.67184
Source DB: PubMed Journal: Theranostics ISSN: 1838-7640 Impact factor: 11.600
A summary of some representative LFIAs by size-controlled noble metal nanoparticles.
| Size range of AuNPs | Optimal size | Analyte | LOD | Ref. |
|---|---|---|---|---|
| 20-39 nm | 39 nm | Progesterone | No given |
|
| 40-150nm | 80 nm | DNA | 50 fmol |
|
| 10-40 nm | 20 nm | Prostate acid phosphatase | 0.25 ng mL-1 |
|
| 6.4-52 nm | 33.4 nm | Potato virus X | 3 ng mL-1 |
|
| 14-38 nm | 38 nm | Hepatitis B surface antigen | No given |
|
| 34-137.8 nm | 42.7 nm | Hepatitis B surface antigen | 10 ng mL-1 |
|
| 20-180 nm | 100 nm | Ochratoxin A | 0.27 ng mL-1 (IC50) |
|
| 30-100 nm | 100 nm | C-reactive Protein | 1.6 pM |
|
| 16-115 nm | 115 nm | Cardiac troponin I | 0.03 ng mL-1 |
|
A summary of some representative LFIAs based on the metal in-situ growth strategy.
| Noble metal growth | Analyte | Dynamic range | LOD | Ref. |
|---|---|---|---|---|
| Gold growth | Atrazine | No given | 1 ng mL-1 |
|
| HCG | No given | 0.3 mIU mL-1 |
| |
| DNA of | 0.39-3.13 nM | 0.4 nM |
| |
| 5×103-1.6×105 CFU mL-1 | 5×103 CFU mL-1 |
| ||
|
| 103-108 CFU mL-1 | 104 CFU mL-1 |
| |
| 1.25×102-2.5×105CFU mL-1 | 12.5 CFU mL-1 |
| ||
| Silver growth | Cardiac troponin I | No given | 0.016 ng mL-1 |
|
| Abrin-a | 0.1-100 ng mL-1 | 0.1 ng mL-1 |
| |
| H5N5 | 0.5-250 ng mL-1 | 0.5 ng mL-1 |
| |
| Avian influenza virus | 21-2-9 dilution | 2-12 dilution |
| |
| Newcastle disease virus | No given | 2-10 dilution | ||
| Fumonisin B1 | No given | 2 ng mL-1 |
| |
|
| 2×103-2×106 CFU mL-1 | 2×102 CFU mL-1 |
| |
| Prostate specific antigen | No given | 0.1 ng mL-1 |
| |
| Potato leafroll virus | No given | 0.2 ng mL-1 |
| |
| Troponin I | No given | 0.24 ng mL-1 |
| |
| Copper growth | HCG | 1 pg mL-1-100 ng mL-1 | 1 pg mL-1 |
|
| p24 antigen | 50 fg mL-1-1 ng mL-1 | 50 fg mL-1 |
| |
| No given | 6 CFU mL-1 |
A summary of some representative LFIAs by engineering the shape of noble metal nanoparticles.
| Methods | Signal | Analyte | Dynamic range | LOD | Ref. |
|---|---|---|---|---|---|
| Multibranched nanostructures | Colorimetry | Aflatoxin B1 | 0.5-25 pg mL-1 | 4.17 pg mL-1 (IC50) |
|
| Colorimetry | No given | 103 CFU mL-1 |
| ||
| Colorimetry | OTA | No given | 0.61 ng mL-1 (IC50) |
| |
| Colorimetry | Influenza A | No given | 67 ng mL-1 |
| |
| SERS | -nucleoprotein | 6.7 ng mL-1 | |||
| Colorimetry | HCG | 9-2304 mIU mL-1 | 9 mIU mL-1 |
| |
| Colorimetry | S-100β | 0.1-100 ng mL-1 | 5.0 pg mL-1 |
| |
| Hollow nanostructures | Colorimetry | Clenbuterol | No given | 2 ng mL-1 |
|
| Colorimetry | IgG | 0.5-50 ng mL-1 | 0.1 ng mL-1 |
| |
| Nanorods | LSPR shift | ErbB2 antigen | No given | No given |
|
| Colorimetry | 102-106 CFU mL-1 | 100 CFU mL-1 |
| ||
| Colorimetry |
| 102-106 CFU mL-1 | 75 CFU mL-1 |
| |
| SERS |
| 102-5×106 CFU mL-1 | 50 CFU mL-1 |
| |
| Fluorescence | Prostate-specific antigen | 3-10 ng mL-1 | 1.07 pg mL-1 |
| |
| Nanoprisms | Temperature | HCG | 35-7000 mIU mL-1 | 2.8 mIU mL-1 |
|
| Multiplexed LFIA | Colorimetry | Dengue virus | No given | 150 ng mL-1 |
|
| Yellow fever virus | No given | ||||
| Ebola virus | No given | ||||
| Colorimetry | Ovalbumin | No given | 0.1 ng mL-1 |
| |
| Hazelnut allergen | No given | ||||
| Casein | No given | ||||
| Colorimetry | Fumonisin B1 | 4-80 ng mL-1 | 3.27 ng mL-1 |
| |
| Zearalenone | 0.8-40 ng mL-1 | 0.70 ng mL-1 | |||
| Ochratoxin A | 0.2-2 ng mL-1 | 0.10 ng mL-1 | |||
| Aflatoxin B1 | 0.1-1.25 ng mL-1 | 0.06 ng mL-1 |
A summary of some representative LFIAs using elemental composition-controlled noble metal nanoparticles.
| Element | Analyte | Dynamic range | LOD | Ref. |
|---|---|---|---|---|
| Pt | HCG | 0.1-9 ng mL-1 | 0.2 ng mL-1 |
|
| HCG | No given | 0.3 ng mL-1 |
| |
| Dehydroepiandrosterone | 1-1000 ng·mL-1 | 10.0 ng mL-1 |
| |
| IrO2 | IgG | No given | 0.07 μg mL-1 |
|
| Salbutamol | 0.18-12 ng mL-1 | 0.002 ng mL-1 |
| |
| Au-Ag | Cadmium ion | 0.05-25 ng mL-1 | 0.05 ng mL-1 |
|
| Penumolysin | No given | 1 pg mL-1 |
| |
| Chloramphenicol | 1.36-123.21 ng mL-1 | 0.36 ng mL-1 |
| |
| Thiamphenicol | 0.80-95.29 ng mL-1 | 0.20 ng mL-1 | ||
| Florfenicol | 2.09-71.53 ng mL-1 | 0.78 ng mL-1 | ||
| Prostate‑specific antigen | 0.3-10.00 ng mL-1 | 0.20 ng mL-1 |
| |
| Au-Pt | Prostate‑specific antigen | 10-200 pg mL-1 | 20 pg mL-1 |
|
| p24 | 1-10000 pg mL-1 | 0.8 pg mL-1 |
| |
| Rabbit IgG | 0.05-10 ng mL-1 | 5 pg mL-1 |
| |
|
| No given | 300 CFU mL-1 |
| |
| Potato virus X | No given | 4-8 pg mL-1 |
| |
| Pt-Ni(OH)2 | Acetochlor | 0.1-20 ng mL-1 | 0.63 ng mL-1 |
|
| 1.0-150 ng mL-1 | ||||
| Fenpropathrin | 0.1-20 ng mL-1 | 0.24 ng mL-1 |
| |
| 1.0-150 ng mL-1 | ||||
| Pt-Pd | p53 Protein | 0.1-10 ng mL-1 | 0.05 ng mL-1 |
|
| 10-107 CFU mL-1 | 34 CFU mL-1 |
| ||
| 1×103-1×106 CFU mL-1 | 9.0×102 CFU mL-1 |
| ||
| Butyrylcholinesterase | 0.05-6.4 nM | 0.025 nM |
| |
| Au-Ag-Pt | Myoglobin | 6.67-150 ng mL-1 | 5.47 ng mL-1 |
|
| FPNHs | H-FABP | No given | 0.21 ng mL-1 |
|
| Dicofol | 23.98-478.32 ng mL-1 | 9.9 ng mL-1 |
| |
| 3.97-91.47 ng mL-1
| 1.59 ng mL-1 | |||
| Glycoprotein | 2-1000 ng mL-1 | 0.18 ng mL-1 |
| |
| Cystatin C | 0.12-500 ng mL-1 | 0.61 ng mL-1 |
| |
| 0.12-500 ng mL-1 | 0.24 ng mL-1 | |||
| MPNHs | Anti-HCV | 0.24-120 pg mL-1 | 0.24 pg mL-1 |
|
| Treponema pallidum antigens | No given | 1 NCU mL-1 |
| |
| Single nucleotide polymorphism | 5 ng-1200 ng per test | 5 ng per test |
| |
| Single nucleotide polymorphisms | 0.02-2 pg μL-1 | 0.04 pg μL-1 |
| |
| β-conglutin | 10 fM-100 pM | 8 fM |
| |
| H1N1 | No given | 50 pfu mL-1 |
| |
| HAdV | No given | 10 pfu mL-1 | ||
| HCG | 0-50 mIU mL-1 | 0.2 mIU mL-1 |
| |
| HCG | 0.01-4 mIU mL-1 | 0.0094 mIU mL-1 |
| |
| 102-105 CFU mL-1 | 9 × 101 CFU mL-1 |
A summary of external structure-controlled noble metal nanoparticles based LFIA.
| Structure | Analyte | Dynamic range | LOD | Ref. |
|---|---|---|---|---|
| Core-shell | Phenylethanolamine A | No given | 0.32 pg mL-1 |
|
| Salbutamol | No given | 3.0 pg mL-1 |
| |
| 2.7-2.7×106 CFU mL-1 | 27 CFU mL-1 |
| ||
| Respiratory infection virus | 1 pM-50 nM | 0.03-0.041 pM |
| |
| Pseudorabies virus | 41-650 ng mL-1 | 5 ng mL-1 |
| |
| Pharmaceutical diclofenac | No given | 0.07 pg mL-1 |
| |
| Clenbuterol | 0-1 ng mL-1 | 5 ng mL-1 |
| |
| Myoglobin | 0.01-500 ng mL-1 | 3.2 pg mL-1 |
| |
| Cardiac troponin I | 0.01-50 ng mL-1 | 0.44 pg mL-1 | ||
| Creatine kinase-MB isoenzymes | 0.02-90 ng mL-1 | 0.55 pg mL-1 | ||
| Cardiac troponin I | No given | 0.1 ng mL-1 |
| |
| Mycoplasma pneumoniae (IgM) | 0.1 ng -10 μg mL-1 | 0.1 ng mL-1 |
| |
| Mycoplasma pneumoniae | 0.1-10 mg mL-1 | 0.1 ng mL-1 | ||
| Cardiac troponin I | 0.09-50 ng mL-1 | 0.09 ng mL-1 |
| |
| Core-statellite | Aflatoxin B2 | No given | 0.9 ng mL-1 |
|
| rabbit IgG | 0.05-2 ng mL-1 | 0.01 ng mL-1 |
| |
| HCG | No given | 0.039 mIU mL-1 |
| |
| MicroRNA | No given | 10 pM |
| |
| HCG | No given | 1.6 mIU mL-1 |
| |
| Clenbuterol | 0.1-2 ng mL-1 | 0.1 ng mL-1 |
| |
| C-reactive protein | No given | 0.08 ng mL-1 |
| |
| Influenza A | No given | 2.5×10-2 HAU mL-1 |
| |
| 17β-estradiol | No given | 0.5 ng mL-1 |
| |
| Nanoaggregates | HIV-1 | No given | 0.1 nM |
|
| Nucleoside | No given | 20 µM |
| |
| p24 antigen | 0.1 fg mL-1-10 ng mL-1 | 0.01 fg mL-1 |
| |
| Methamphetamine | 0.023-375 ng mL-1 | 0.026 ng mL-1 |
| |
| HCG | 0.49-1000 mIU mL-1 | 0.49 mIU mL-1 |
| |
| Hepatitis B surface antigen | 0.46-1000 ng mL-1 | 0.45 ng mL-1 | ||
| Troid-stimulating hormone | 0.4-40 μIU mL-1 | 0.5 μIU mL-1 |
|